<DOC>
	<DOCNO>NCT01906307</DOCNO>
	<brief_summary>Hepatorenal syndrome ( HRS ) life-threatening condition mark rapid decline kidney function patient liver cirrhosis fulminant liver failure . Vasodilation gastrointestinal region largely think contribute disease . LJPC-501 vasoconstrictor may restore proper circulation kidney function patient HRS .</brief_summary>
	<brief_title>A Phase 1 Study LJPC-501 Patients With Hepatorenal Syndrome</brief_title>
	<detailed_description>Vasoconstrictors consider promising approach treat HRS due significant vasodilation splanchnic circulation contributes systemic arterial underfilling lead functional decline kidney patient . Vasoconstrictors currently use associate reduced organ perfusion marginal effect sodium excretion . The vasoconstrictor angiotensin II show produce significant sodium excretion urine output patient cirrhosis ascites , support potential utility treatment HRS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hepatorenal Syndrome</mesh_term>
	<criteria>1 . Patients HRS , define International Ascites Club [ 1 ] : Cirrhosis ascites Serum creatinine &gt; 1.5 mg/dL No improvement serum creatinine ( decrease level â‰¤ 1.5 mg/dL ) least 2 day diuretic withdrawal volume expansion albumin Absence shock No current recent treatment nephrotoxic drug Absence parenchymal kidney disease , indicate proteinuria &gt; 500 mg/day , microhematuria ( &gt; 50 red blood cell per high power field ) and/or abnormal renal ultrasonography Or patient HRS due acute alcoholic hepatitis 2 . Patient able undergo reliable neurologic exam , determine investigator 3 . Patient legal surrogate willing able provide write informed consent 4 . Patient willing able comply protocol requirement 1 . Evidence shock 2 . Current recent treatment nephrotoxic drug 3 . Use midodrine , octreotide , vasopressor within 48 hour screen 4 . Current treatment dialysis 5 . Serum creatinine &gt; 7 mg/dL 6 . Active cardiovascular disease within 3 month screen 7 . History transient ischemic attack prior stroke 8 . History organ transplant 9 . Ongoing infection require intravenous administration antibiotic ( patient document infection consider Investigator control within 48 hour screen may permit study upon consultation Sponsor 's Medical Monitor ) 10 . Participation clinical trial within 30 day screen 11 . Patient unlikely survive 72 hour opinion investigator 12 . Patient pregnant planning become pregnant study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>hepatorenal syndrome</keyword>
</DOC>